Earnings Call Summary | Dyadic(DYAI.US) Q1 2024 Earnings Conference
Earnings Call Summary | Dyadic(DYAI.US) Q1 2024 Earnings Conference
The following is a summary of the Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript:
以下是Dyadic International，Inc. (DYAI) 2024年第一季度業績會交流摘要:
Financial Performance:
金融業績：
Dyadic International closed a $6 million convertible note financing in the first quarter with no issuance of warrants.
Research and development revenue decreased from approximately $934,000 in Q1 2023 to $335,000 in Q1 2024 due to the winding down of several large research collaborations.
The company reported a net loss of approximately $2 million or $0.07 per share for Q1 2024.
第一季度Dyadic International通過可轉換債券融資，獲得600萬美元，未發行認股權證。
由於幾個大型研究合作項目接近尾聲，第一季度研發收入從2023年第一季度的約934,000美元降至2024年第一季度的約335,000美元。
2024年第一季度，公司報告淨虧損約200萬美元，每股虧損0.07美元。
Business Progress:
業務進展：
The company is advancing 12 projects, including antigen vaccines in collaboration with two top-pharmaceutical companies.
It has secured fully funded collaborations and has ongoing developments in human health. A significant achievement was the completion of a Phase 1 clinical trial demonstrating safety and antibody response for DYAI100.
In animal health, Dyadic has partnered with ViroVax on a bird flu vaccine that has shown effectiveness against various virus variants. This vaccine can be rapidly mass-produced at a low cost.
Dyadic's novel C1 technology continues to attract attention for its productivity, speed, and cost-effectiveness.
The firm is expanding its presence in alternative protein and bio-industrial sectors, with the newly launched Dapibus exceeding initial expectations.
It is focusing on potential revenue share to infiltrate different market segments and considering various financial models including milestones and royalties.
Dyadic is planning to finalize an agreement for albumin production with a partner that offers low-cost downstream processing capability.
They have decided not to progress with DYAI-100 as a COVID-19 booster vaccine, instead focusing on the development of vaccines with greater efficacy and potentially universal application.
The company is focused on expanding the use of their C1 and Dapibus platforms for protein production in human health, animal health, and alternative protein sectors.
公司正在與兩家頂尖製藥公司合作研發抗原疫苗等12個項目，其人類健康領域項目已獲得全資支持，其中DYAI100已完成一期臨床試驗，證明其安全性和抗體反應成效顯著。
公司在人類健康領域擁有完全資助的合作研究，並在盈健醫療領域進行持續開發。其中一個重要成就是完成了DYAI100安全性和抗體反應的一期臨床試驗。
在動物健康領域，Dyadic與ViroVax合作開發禽流感疫苗，已證明其對多種病毒變種具有顯著效果，該疫苗可高效低成本地大規模生產。
Dyadic的創新C1技術因其生產效率、速度和成本效益引起關注。
公司正在擴大在另類蛋白質和生物-工業領域的影響力，新推出的Dapibus業務已經超過了最初預期。
公司正在專注於通過潛在的收入分成方式滲透不同的市場細分領域，並考慮包括里程碑和版稅在內的各種財務模式。
Dyadic計劃與具備低成本下游處理能力的合作伙伴就白蛋白生產達成協議。
公司決定不將DYAI-100作爲COVID-19增強疫苗，而是專注於開發更有效且可能具有普遍應用性的疫苗。
公司專注於擴大其C1和Dapibus平台在人類健康、動物健康和另類蛋白質領域的蛋白質生產應用。
More details: Dyadic IR
更多詳情：Dyadic IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。